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Epstein-Barr virus (EBV) driven post-transplant lymphoproliferative disease (PTLD) is a heterogeneous and potentially life-
threatening condition. Early identification of aberrant EBV activity may prevent progression to B-cell lymphoma. We measured
EBV DNA load and RNA profiles in plasma and cellular blood compartments of stem cell transplant (SCT; n = 5), solid
organ transplant recipients (SOT; n = 15), and SOT having chronic elevated EBV-DNA load (n = 12). In SCT, EBV DNA
was heterogeneously distributed, either in plasma or leukocytes or both. In SOT, EBV DNA load was always cell associated,
predominantly in B cells, but occasionally in T cells (CD4 and CD8) or monocytes. All SCT with cell-associated EBV DNA showed
BARTs and EBNA1 expression, while LMP1 and LMP2mRNAwas found in 1 and 3 cases, respectively. In SOT, expression of BARTs
was detected in all leukocyte samples. LMP2 and EBNA1 mRNA was found in 5/15 and 2/15, respectively, but LMP1 mRNA in
only 1, coinciding with severe PTLD and high EBV DNA. Conclusion: EBV DNA is diﬀerently distributed between white cells and
plasma in SOT versus SCT. EBV RNA profiling in blood is feasible and may have added value for understanding pathogenic virus
activity in patients with elevated EBV-DNA.
1. Introduction
Posttransplant lymphoproliferative disease (PTLD) is a
severe, (pre-)malignant complication in transplant recip-
ients, caused by Epstein-Barr-virus- (EBV-) driven B-cell
proliferation in periods of defective T-cell mediated immune
surveillance [1–3]. The pivotal role of EBV in PTLD
pathogenesis is illustrated by the expression of EBV latent
genes within PTLD lesions, including the abundant small
noncoding EBER1, 2 RNA, and the essential EBNA1 protein
being present in all proliferating B cells, and EBNA2 and
LMP1 oncogenes being expressed in only a subset of these
cells [2, 3]. At the single cell level, EBV gene expression
in PTLD tissues may be heterogeneous, with coexistence
of diﬀerent EBV latency types as revealed by EBNA2
and LMP1 double staining immunohistochemistry [4, 5].
This heterogeneity relates to PTLD cell morphology, with
relatively small PTLD cells expressing EBNA2 in the absence
of LMP1, intermediate-sized cells express both EBNA2 and
LMP1 (latency-III or growth program), and with larger
immunoblastoid PTLD cells expressing LMP1 only in the
absence of EBNA2 (i.e., default program or latency type
II). The latter cells predominate and may have Hodgkin’s
Reed-Sternberg (HRS) cell-like morphology and a high
proliferative capacity. In addition, occasionally cells show
evidence of lytic viral replication [5, 6].
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PTLD aﬀects both solid organ (SOT) and stem cell (SCT)
transplant recipients, but diﬀers in pathogenesis. In EBV
naı¨ve SOT patients, the virus can be derived from the graft,
blood transfusions, and external sources. However, in EBV
carrying SOT recipients PTLD generally originates from
reactivating endogenous virus from latently infected B cells
of the host itself and frequently localises to the transplanted
organ [7]. In SCT patients, EBV might be mostly derived
from donor B cells or exogenous sources, since the endoge-
nous virus can be cleared by pretreatment conditioning
regimes [8]. In addition, paediatric patients developing
PTLD frequently are virus negative prior to transplantation
indicating EBV to originate from donor materials. In SCT
EBV-driven PTLD causes a more diﬀuse and systemic disease
initially resembling infectious mononucleosis or tonsillitis
and may present at multiple locations. PTLD in SCT usually
develops early after transplantation due to severe immuno-
suppression and delayed immune reconstitution [9].
Although PTLD is a highly progressive disease, it can
be reverted at early stages, and preemptive treatment is
indicated. This can be achieved by temporary lowering of
immunosuppression, by infusion of EBV-reactive T cells or
by Rituximab treatment combined with reduced immune
suppression [9]. Most PTLD patients show elevated levels of
EBV DNA in blood before onset of the disease. EBV DNA
loadmonitoring enables identification of the earliest stages of
EBV-driven B-cell hyperplasia [10–12]. EBV DNA is located
either in circulating cells or is present as cell-free fragmented
DNA in plasma. There is no evidence of EBV-DNA being
associated with cell-free infectious virions in blood. Cells
harbouring EBV DNA are likely to be B cells [13–15], but
occasionally T cells, monocytes, and immature dendritic cells
can be infected as well [16–18]. Whether circulating EBV
carrying cells in PTLD patients directly reflects the tissue-
bound PTLD cells in terms of viral gene expression is not
well defined [19]. A role for lytic EBV replication in PTLD
initiation is indicated in mouse models [20, 21], but may not
be relevant in transplant settings using prophylactic antiviral
agents [11, 12, 22, 23]. In fact, very little is known about
gene-expression profiles in circulating EBV-positive B cells
during (early stages of) PTLD and related lymphoprolifer-
ative disorders. Generally a direct concordance is assumed
between tissue-associated and circulating B cells, but this
remains to be established more firmly.
The aim of this study was to define the viral DNA
compartmentalisation in blood cells or plasma (or both)
and to describe viral gene expression patterns in circulating
lymphoid cells in SCT and SOT recipients with and without
PTLD. Therefore, unfractionated whole blood, plasma, and
isolated B- and T-cell fractions were quantitatively anal-
ysed for EBV DNA. In addition, we determined the EBV
transcriptional phenotype in blood of PTLD patients and
patients with early stage B-cell hyperplasia as identified by
circulating EBV DNA load elevations.
2. Materials and Methods
2.1. Clinical Specimens. Clinical samples were obtained from
stem cell transplant recipients at the University Medical
Center Utrecht, the Netherlands, and Erasmus Medical Cen-
ter, Rotterdam, the Netherlands, and from lung transplant
recipients at the University Medical Centre, Groningen, the
Netherlands. Whole blood samples were collected prospec-
tively as part of the routine diagnostic monitoring in both
SOT (n = 15) and SCT patients (n = 5) using standard pro-
cedures that have been described before [22, 23]. Data from
SOT patient 1 (Figure 3) were described in part previously
[11]. Larger blood samples for this study were taken at the
earliest time point of confirmed and sustained elevated EBV-
DNA load above the clinical cutoﬀ, indicative of early-stage
PTLD [24]. PTLD was confirmed by EBER-RISH on biopsy
specimens as previously described [11, 22, 23]. Additionally,
in some SOT patients, whole blood samples (n = 12) were
collected during episodes of persistent high EBV-DNA load
at least 6 months after transplantation (Table 1). As control
for cell fractionation and FACS-analysis, whole blood and
peripheral blood mononucvlear cell (PBMC) samples from
a healthy EBV carrier (n = 1) and from a patient with
EBV-positive (Granzyme-B positive) NK/T-cell lymphoma
(n = 1) were collected as well [3, 24].
For DNA and RNA analysis 100 μL whole blood was
added to 900 μL NucliSens lysis buﬀer (BioMerieux, Box-
tel, The Netherlands) directly upon collection and stored
at −80◦C. Plasma was separated from whole blood by
centrifugation and stored at −20◦C. PBMCs were isolated
from whole blood by standard Lymphoprep centrifugation
(Greiner Bio-one, Nuremberg, Germany). PBMCs were
stored at approximately 5 × 106 cells/mL in liquid nitrogen
in 10% DMSO- RPMI-1640 medium (BioWhittaker, Basel,
Switzerland, containing 20% FCS (Hyclone, South Logan,
UT)).
2.2. Cell Separations Procedures. Upon thawing, viable
peripheral blood mononuclear cells (PBMC) were reiso-
lated by density gradient centrifugation over Lymphoprep
(Greiner Bio-one). On average 5×106 PBMCs were used per
donor. For the isolation of the B and T cells, two diﬀerent
procedures were performed. In the first method PBMCs
were sorted in CD20, CD4, CD8, and monocytes by FACS
sorting. Monoclonal antibodies against CD20, CD4, CD8,
and CD14 were conjugated to, respectively, phycoerythrin
(PE), allophycocyanin (APC), Peridinin Chlorophyll-a pro-
tein (PerCp), and fluorescein isothiocyanate (FITC) and were
purchased from BD biosciences (Franklin Lakes, NJ). Cells
were incubated with moabs for 15min on ice. After two
washing steps with PBS, cells were resuspended and sorted
by FACS-Calibur. During FACS sorting, measurements were
performed to check the purity of the populations. FACS data
were analyzed with DIVA software (Diva). Gating of the cells
was calibrated with sorted populations prepared from frozen
PBMCs of a single healthy individual during each experiment
and used in all sorting experiments. The sorted cells were
counted and added to 0.2mL RNABee (AMS Biotechnology,
Oxon, UK). In the second method, B-lymphocytes were
isolated from PBMC by CD19 Dynabead M-450 selection
(Dynal Biotech, Smestad, Norway) according to the manu-
facturer’s protocol. From the remaining cells (designated as
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Table 1: SOT patients with chronic high viral load. Primary infection after transplantation is indicated.
Patient
Age
Gender Primary disease
Time after LTx Primary EBV infection
Years Years 0 = no, 1 = yes
1 57 M Extrinsic allergic alveolitis 14 0
3 13 M Cystic fibrosis 5 1
4 21 M Cystic fibrosis 3 0
5 19 F Cystic fibrosis 12 0
7 41 M Alpha-1-AT deficiency 11 0
8 32 M Cystic fibrosis 6 0
9 52 M Emphysema 11 0
10 23 M Cystic fibrosis 2 1
12 36 F Cystic fibrosis 6 0
14 42 M Alpha-1-AT deficiency 12 0
15 46 M Alpha-1-AT deficiency 11 0
16 9 M Cystic fibrosis 2 1
“non-B-cell fraction”), the T-cell and monocyte-cell popu-
lations were sorted by FACS using monoclonal antibodies
against CD4, CD8, and CD14 as described above. The cell
populations were counted and added to 0.2mL RNABee.
2.3. EBV DNA and RNA Isolation. DNA and RNA were
isolated from clinical samples collected and stored in
NucliSens lysis buﬀer by silica-based extraction as described
previously [25]. For nucleic acid isolation 100 μL, whole
blood material was added to 900 μL Nuclisens lysis buﬀer.
After silica-based nucleic acid extraction according to the
manufacturer’s instruction, DNA and RNA were eluted in
100 μL. In addition, for increasing the concentration in PCR
of DNA from plasma specimens, DNAwas isolated by Qiamp
DNA blood mini kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. RNA from cellular origin
was isolated using RNABee (AMS Biotechnology, Oxon, UK)
as described by the manufacturer.
2.4. EBV DNA Load Quantification. EBV DNA copy num-
bers in clinical samples were determined using standardized
quantitative LightCycler-based real time PCR assays, target-
ing conserved 213 bp (intact virion DNA) or a 99 bp regions
(detects fragmented apoptotic virion DNA as well) of the
viral EBNA1 gene, as described in detail [26, 27].
2.5. EBV RNA Amplification. EBV-encoded transcripts for
EBNA1 (QK splice variants), LMP1, LMP2a and b, BARTs,
BZLF1 (ZEBRA), and the cellular low-copy U1A snRNP
transcript were detected using a two-step RT-PCR assay
consisting of a gene-specific multiprimed cDNA synthesis
followed by PCR amplification as described previously [28].
PCR products were loaded onto a agarose gel and blotted on
nylon membrane. The membrane was used for hybridization
with the specific γ32P-ATP labelled oligonucleotide probes
to determine their specificity. As a positive control, U1A
snRNP RT-PCR was performed on all samples as described
previously.
2.6. Statistical Analysis. The level of viral load in plasma was
compared to whole blood. The significance of diﬀerences
between categories was analyzed by means of the 2-tailed
Wilcoxon signed-rank test. P values <0.05 were considered
to be significant.
3. Results
3.1. EBV Viral DNA Load in Plasma and Whole Blood. EBV
DNA loads were determined in the circulation of early onset
and established PTLD patients. The DNA was measured in
diﬀerent compartments in the blood of SCT patients (n = 5)
compared to SOT patients (n = 12). In the SCT patients, the
viral DNA load was analysed weekly after stem cell transplan-
tation in whole blood and plasma (Figure 1). EBV DNA load
was determined in plasma by the 99 bp LC PCR to enable
detection of fragmented DNA, whereas the 213 bp LC PCR
was used for analysing intact virion DNA for cell associated
EBV in whole blood. Plasma EBV DNA load was cross-
sectionally compared with EBV DNA load in PBMC. Highly
variable results were seen comparing PBMCs to the plasma
levels of EBV DNA (Table 1). The most extremes were the
total absence of EBV DNA in plasma of an SCT patient and a
DNA load of 1.4× 106 copies/106 cells in the simultaneously
obtained PBMC sample, indicating that EBV DNA was cell
associated. However, the contrary was also observed, with
high levels in plasma (3.7× 105 copies/mL) and undetectable
levels of EBV DNA in PBMC fraction of the same patient.
No clear relation was found between EBV DNA copies in the
whole blood (or PBMCs) and the plasma of the SCT patients.
In the SOT patients, the EBV DNA load was mainly
detected in whole blood (Figure 2) and only sporadically in
plasma. In most cases, the whole blood contained higher
levels EBV DNA copies than the parallel plasma (P = 0.028).
This showed that the circulating EBV DNA is mostly cell
associated in SOT patients.
3.2. EBV RNA Profiling of Circulating Cells in Transplant
Patients. In SCT patients having high levels of EBV DNA
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Figure 1: EBV RNA expression analysis in follow-up PBMC samples from SCT recipients in relation to plasma EBVDNA load kinetics. Viral
DNA load in plasma was monitored by quantitative RT-PCR after stem cell transplantation (y-axis). At the indicated time point viral load
was determined in plasma as well as in PBMCs. Presence of BARTs, EBNA1, LMP1, and 2 RNA was analysed by RT-PCR in 10e6 PBMCs.
in the cellular fraction (4 patients), EBNA1 and BART RNA
could be detected (Figure 1). Three of the patients had LMP2
positivity, whereas LMP1 RNA was not detectable. One
patient had LMP1 expression but LMP2 RNA was absent.
The patient without EBV load in the cellular fraction, who
was however positive for EBV DNA in the plasma (3.8 ×
105 copies/mL), showed no expression of EBV related RNAs
in the whole blood sample.
Since the elevated EBV DNA loads in SOT patients were
largely associated with circulating cells, the transcriptional
phenotype of EBV was analysed in the PBMCs of SOT
patients. Two patients were followed in time after they
received a lung transplantation. EBV DNA load and RNA
analysis is shown in Figure 3. From a larger group of
SOT patients (n = 15) with suspected PTLD early after
transplantation, RNA profiles were analyzed in whole blood
samples at time points of elevated (rising) EBV DNA load,
prior to reducing immune suppression as a preemptive
treatment. For analyzing the transcriptional activity of EBV,
multiprimed RNA profiles were made as described earlier
[28]. BART RNA was detected in all cases, whereas EBNA1
was only detectable in 2 subsequent samples in one patient.
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Figure 2: EBV DNA load analysed by quantitative PCR in whole
blood compared to plasma of SOT patients (n = 15).
Transcription of the major EBV-encoded oncogene LMP1 in
circulating cells was only seen in 1 patient and coincided
with peak levels in EBV DNA load and coexpression with
the LMP2 gene at end-stage PTLD, which was confirmed by
tissue biopsy. The expression of LMP2 RNA was temporarily
detected in 5 additional patients, who had a reversible PTLD,
confirmed by the detection of EBER-RNA in the biopsy but
disappearing after lowering immunosuppression. No ZEBRA
mRNA was detected (data not shown).
3.3. DNA and RNA Analysis in Patients with Chronic High
EBV Load after SOT. An additional group of SOT patients
(n = 12) did not show episodes of PTLD, although the EBV
DNA levels persisted at a high level (>2000 c/mL blood) for
several weeks. Overall, these patients were monitored for a
period of 1–14 years after transplantation. The immune sup-
pression of all cases was preemptively lowered after detecting
twice an elevated (>2000 c/mL) and increasing EBV viral
load. Results are shown in Table 2. The RNA from PBMCs
was positive in all cases for the low copy number cellular U1A
transcript serving as an internal positive (quality) control.
Among the EBV specific RNAs detected were BARTS in 10/12
of cases and LMP2 mRNA in 2/10 cases, whereas LMP1
mRNA was detected in only 1 patient during high levels
of circulating EBV DNA load with EBV DNA presence in
both plasma and PBMC fractions. There was no indication
of circulating dividing infected cells in any of the patients,
since the expression of Qp-driven EBNA1 RNA could not be
detected. Viral lytic replication was absent as well since the
ZEBRA mRNA was negative in all samples.
3.4. Origin of EBV DNA in SOT Patients with Chronic High
EBV DNA Load. Chronic high levels of circulating cell-
associated EBV DNA were observed in a subset of SOT
patients (n = 8). The origin of the persistent high DNA loads
was unclear and no signs of localised PTLD or progressive
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Figure 3: EBV RNA expression analysis in follow-up PBMC
samples from two SOT recipients in relation to EBV DNA load
kinetics. Viral load in whole blood was monitored by quantitative
PCR after solid organ transplantation. Presence of BARTs, EBNA1,
LMP1, and 2 RNA was analysed by RT-PCR in 106 PBMCs at the
indicated time points.
Table 2: EBV DNA load determination by LightCycler PCR
in simultaneously collected plasma and PBMC samples of 5
representative SCT patients.
SCT patient
EBV DNA load in
plasma (copies/mL)
EBV DNA load in PBMC
(copies/106 cells)
1 0 1426344
2 3740 6216
3 376000 0
4 26900 17471
5 20100 109
systemic lymphoproliferation was detected. Therefore, the
origin and cellular distribution of the elevated circulating
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EBV DNA was analysed. Stored PBMCs were isolated and
subsequently sorted into B and T cells. The cell sorting was
performed in 3 patients using CD19 beads to select the B
cells after which the non-B-cell fraction was sorted by FACS
into CD4 and CD8 T-cells and monocytes. In the other 5
patients, PBMCs were directly sorted by FACS into CD20
(B cell), CD4-, and CD8-positive (T cell) and CD14 positive
(monocyte) fractions. Gates were determined by the analysis
of sorted PBMC of a healthy donor, frozen in aliquots, and
thawed for each experiment. During FACS sorting, sorted
populations were checked for purity by direct FACS analysis
in between the procedure of sorting. The purity of the cell
fractions ranged from 85% to 100%. The contamination was
analyzed for markers of B and T cells and monocytes. In the
fractions that were not 100% pure, the contaminating cells
were not identified as B, T cells, or monocytes (all <1%).
PBMCs of a patient with EBV-positive NK/T lymphoma,
known to have a high viral load in T cells, were analysed as a
positive control.
The viral DNA load in the sorted cells of the patient
with NK/T lymphoma was located in the B cells (1.2 × 104
copies/105 cells), whereas the CD8 positive T cells (1.6 ×
104 copies/105 cells) and monocytes (2.0 × 104 copies/105
cells), had high levels of EBV DNA as well. Overall in
this patient, monocytes, B cells, and CD8 positive T cells
contained 18%, 1%, and 10% of total circulating EBV-DNA
load, respectively. In the healthy donor, only occasional low
level EBV DNA signals were found in the purified B-cell
fraction. The EBV DNA load in PBMCs of 6 SOT patients
with elevated whole blood loads was present in the B cells
and EBV DNA was neither detectable in the T cells nor in the
monocytes (Figure 4). In 2 patients (indicated by 1 and 2 in
Figure 4), some EBV DNA could be detected in the T cells
as well as in the monocytes, in addition to a high viral load
in the B cells (Figure 4(a)). In these 2 patients, the overall
level of viral DNA in PBMC only partly originated from B
cells, since the percentage of B cells in the PBMC fraction
was low (1–5%) compared to the amount of T cells (∼30%)
and monocytes (∼20%). Although T cells harboured a lower
amount of EBV DNA per cell equivalent, their contribution
to the absolute viral load in whole blood may be high due
to the higher numbers of T cells compared to B cells. The
monitoring of the viral load in the PBMCs determined in
these two patients after transplantation and the time of
sampling for FACS sorting is represented in Figure 4(b). Due
to limited sample sizes, no detailed RNA profiling could
be done on isolated PBMC subfractions. The overall whole
blood RNA patterns are shown in Table 3.
4. Discussion
This study shows that although both in SOT and SCT
patients the development of PTLD is preceded by increases
of EBV DNA load, the underlying biology of EBV-driven cell
proliferation in SCT and SOT is diverse. In SOT patients
the viral DNA is largely cell associated, whereas in blood
of SCT patients either cell-associated or cell-free EBV DNA
or (mostly) both can be detected. RNA profiles in the SCT
patients were complex showing the expression of BARTs,
EBNA1, and occasionally LMP1 and LMP2. Likely due to
the higher immune suppression in the SCT patients, the EBV
positive B cells are less silenced in their viral gene expression
than in the SOT patients. Interestingly, the RNA expression
profiles in circulating cells seem to show a more restricted
pattern as compared with the PTLD biopsy [4–6], suggesting
EBV transcriptional silencing before circulating cells leave
the lymphoid tissue environment [14, 15]. The absence of
EBNA1 mRNA in most whole blood or PBMC specimens
indicates that the circulating cells are not replicating and
are not simply reflecting the proliferating cells present in
PTLD tissues. This is in line with previous observations and
confirms the current prevailing model of EBV persistence,
where proliferation and latent gene expression are restricted
to lymphoid tissues, even in immunosuppressed individuals
[14, 29, 30].
High and rising levels of EBV DNA are frequently
detected at the onset of clinically apparent PTLD in SCT
patients as well as in SOT patients [8]. However, high EBV
loads alone are not informative for predicting PTLD, as most
patients with chronic and stable high EBV DNA loads in
this study did not develop PTLD [31]. Therefore, monitoring
for dynamic changes in EBV loads is more important in
identifying those at risk for developing PTLD and provides
more relevant information for adapting therapy [11, 22, 23,
31–34]. Although the viral load in SOT patients is largely
cell associated, as demonstrated by us and others previously,
in SCT patients EBV DNA is variably distributed between
cells and plasma [35]. This supports prior studies, showing
that in SCT plasma levels of EBV DNA can be well used for
diagnosis of EBV lymphoproliferation and PTLD risk [36].
However, in some SCT patients plasma can be virus-free with
parallel high levels in PBMC, as demonstrated in Figure 1,
SCT patient 1. Hence, in order to avoid false negative EBV
DNA load results in high risk SCT populations, we and
others have advocated the use of whole blood EBV DNA
testing as the preferred standardised diagnostic approach
[35, 37]. We observed no apparent correlation between the
amount of EBV DNA in plasma and whole blood or PBMC,
since SCT patients with the highest viral loads in plasma were
not necessarily the patients with a high level in the circulating
cells as was suggested earlier [34]. The origin of EBV DNA in
the circulation is not clear, but it may very well be derived
from apoptotic cells shed at early stage in PTLD as detected
in patients with nasopharyngeal carcinoma and Hodgkin’s
disease [38]. On the other hand, apoptotic EBV DNA may
reflect local activity of cytotoxic T cells and provide a signal of
emerging immune responses. In support of this, it has been
shown that EBV DNA in plasma of PTLD patients is cell-free
and nonencapsidated, although nucleosomal fragmentation
was not demonstrated directly [39].
Whole blood can also be used for monitoring PTLD risk
in SOT patients where the EBV DNA is mainly confined
to circulating cells [35, 40]. The cell-associated nature of
EBV DNA in SOT was shown earlier by EBER RNA in situ
staining in circulating B cells of a PTLD patient [11]. Here,
we confirmed the cell association of EBV DNA in SOT, since
EBV DNA levels in parallel plasma samples had values below
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Figure 4: (a) Localisation of EBV DNA in PBMCs of 8 SOT patients sorted into B cells, T cells, and monocytes. As control PBMCs of a
patient with NK/T lymphoma was used, indicated with an asterix. PBMCs were sorted by FACS in monocytes and B and T cells. Viral load
was determined in 10e5 sorted cells. The purity of the sorted cells was higher than 85%. (b) EBV DNA load in follow-up samples of SOT
patients. The arrow indicates the time point of sampling for the analysis of the viral load in the B cells, T cells, and monocytes.
Table 3: RNA profiles in circulation of SOT patients with chronic high EBV loads without PTLD. EBV DNA load and RNA profiles were
analysed in PBMCs. JY and B95-8 are EBV infected B cells with latency 3, which served as positive controls for RNA profile.
Patient
EBV DNA load RT-PCR
(Copies/mL plasma) (Copies/10∗ E6 PBMCs) BARTs EBNA1 QK LMP1 LMP2a LMP2b ZEBRA U1A snRNP
1 54 482 − − − − − − +
3 34 4487 + − − − − − +
4 0 258 + − − − − − +
5 0 923 + − − ± − − +
7 0 382 + − − − − − +
8 45 0 + − − − − − +
9 112 278 + − − − − − +
10 610 177 + − + ± − − +
12 0 76 + − − − − − +
14 21 105 + − − − − − +
15 21 160 + − − − − − +
16 41 126 − − − − − − +
JY RNA na na + + + + + + +
B95-8 RNA na na + + + + + + −
NT na na − − − − − − −
JY DNA na na − − − − − − −
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the COV level in contrast to high viral loads in whole blood.
This is in line with other independent SOT studies [40–
42].
The pathogenesis of PTLD reflects a complex interaction
of EBV-infected cells with the (allogenic) host environ-
ment and rejection-associated inflammatory events. Previ-
ous studies on EBV RNA expression profiling in PTLD
tissue indicated a type III latency (growth program) with
a combined expression of EBNA1 (reflecting proliferating
cells), EBNA2 (reflecting active transformation events), and
LMP1 plus LMP2 (growth activation). In contrast to PTLD
tissue, EBNA1 and LMP1 mRNA is almost never detected
in the circulating cells, whereas LMP2 mRNA can be found
more frequently in circulating cells. Only during early stage
acute primary infection such as latency type III cells has
been directly demonstrated in the circulation [43]. Our data
suggest that the detection of LMP1mRNA in circulating cells
can be considered a danger signal reflecting premalignant
EBV-driven B-cell proliferation, which requires intervention.
In contrast, LMP2 can be detected more frequently and
is also described to be present in healthy individuals [14].
The percentage of LMP2 positive SOT patients is lower
than described earlier [30], but this may be due to the
diﬀerence in age of the patients in the two studies. The
biological activity of circulating EBV positive cells in both
SOT and SCT patients with elevated EBV-DNA loads
seems to diﬀer from the PTLD tissue indicating that EBV
carrying B cells may undergo transcriptional silencing by
methylation of EBV promoters prior to entry into the
circulation.
The RNA profiles in the circulating cells of SCT patients
are more diverse compared to SOT patients. In most SCT
patients, RNA encoding BARTs, EBNA1, and LMP2 was
detectable, whereas in only one patient LMP1 mRNA was
detected. The presence of more viral RNA populations may
be due to a nonfunctioning immune systemwhich is not fully
recovered yet. Therefore, it would be interesting to analyse
whether this reflected the EBV RNA expression in the bone
marrow. However, due to the lack of materials in the present
study, this remains as yet unresolved.
EBV is known to be B-cell associated; however, in chronic
EBV disease it is described that EBV can be detected in non
B cells [3] such as T/NK cells and monocytes [16–18]. In this
study in 13/15 chronic EBV patients, EBVwas predominantly
detected in the B cells. In 2 patients, EBV DNA could also be
detected in the T cells (CD4 and CD8) and monocytes. EBV
infection and functional alteration of monocytes in vitro
which generally do not express the EBV receptor, CD21, was
shown before [44].
In conclusion, our data show that EBV in blood of
transplant patients with (chronic) elevated EBV DNA loads
is mainly confined to B cells which show limited EBV mRNA
expression, supporting the notion that (pre-)malignant
proliferation preferentially occurs in lymphoid tissues or in
the transplanted organ. These cells do circulate, but EBV
genes are probably switched oﬀ prior to entry into the blood
stream. In SOT patients with chronic high EBV DNA load, of
EBV, predominates in the B cells, but can occasionally persist
in T cells as well as the monocytes.
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